Literature DB >> 9792317

Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning.

G Socié1, A Devergie, T Girinski, G Piel, P Ribaud, H Esperou, N Parquet, O Maarek, M H Noguera, P Richard, O Brison, E Gluckman.   

Abstract

We describe the long-term follow-up of 50 Fanconi's anaemia patients who were transplanted from a related donor with a median follow-up of >6 years. The survival estimate was 74.4% at 54 months and 58.5% at 100 months. All patients were conditioned with low-dose cyclophosphamide and thoraco-abdominal irradiation. Acute graft-versus-host disease (GvHD) of grade II or more developed in 26 patients and chronic GvHD developed in 30/43 (69.9%) patients. The survival of patients without chronic GvHD (n = 13) was 100%. In addition to chronic GvHD, 20 pre-transplant transfusions was shown to have an adverse impact on survival by multivariate analysis (relative risk = 7.08, P = 0.0003). Prospective follow-up of growth and endocrine function could be performed in 31 patients. Of 20 boys, six have already reached normal puberty within the expected time. Among the 11 girls, three were at the pubertal age at the time of analysis. Growth retardation was common, whereas late complications (e.g. peripheral hypothyroidism, cataract) were rare. However, the most important long-term complication was the occurrence of cancer in seven patients (8-year projected incidence 24%). Among the 32 survivors, 27 (84.5%) had a normal and four a moderately reduced performance status, and all achieved complete engraftment with donor cells. Therefore transplantation was able to cure these patients who remain at high risk for developing late complications. Clearly, a genetic predisposition and chronic GvHD could have led to the development of these cancers. However, we cannot completely rule out irradiation as a cofactor in the genesis of these cancers, and therefore no longer use irradiation for the conditioning of Fanconi's anaemia patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792317     DOI: 10.1046/j.1365-2141.1998.00968.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.

Authors:  Yue Si; Samantha Ciccone; Feng-Chun Yang; Jin Yuan; Daisy Zeng; Shi Chen; Henri J van de Vrugt; John Critser; Fre Arwert; Laura S Haneline; D Wade Clapp
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.

Authors:  Ricardo Pasquini; Jeanette Carreras; Marcelo C Pasquini; Bruce M Camitta; Anders L Fasth; Gregory A Hale; Richard E Harris; Judith C Marsh; Anibal J Robinson; Mei-Jie Zhang; Mary Eapen; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

3.  Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.

Authors:  Mouhab Ayas; Wael Saber; Stella M Davies; Richard E Harris; Gregory A Hale; Gerard Socie; Jennifer LeRademacher; Monica Thakar; H Joachim J Deeg; Amal Al-Seraihy; Minoo Battiwalla; Bruce M Camitta; Richard Olsson; Rajinder S Bajwa; Carmem M Bonfim; Ricardo Pasquini; Margaret L Macmillan; Biju George; Edward A Copelan; Baldeep Wirk; Abdullah Al Jefri; Anders L Fasth; Eva C Guinan; Biljana N Horn; Victor A Lewis; Shimon Slavin; Polina Stepensky; Marc Bierings; Robert Peter Gale
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

4.  Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Authors:  Mouhab Ayas; Mary Eapen; Jennifer Le-Rademacher; Jeanette Carreras; Hisham Abdel-Azim; Blanche P Alter; Paolo Anderlini; Minoo Battiwalla; Marc Bierings; David K Buchbinder; Carmem Bonfim; Bruce M Camitta; Anders L Fasth; Robert Peter Gale; Michelle A Lee; Troy C Lund; Kasiani C Myers; Richard F Olsson; Kristin M Page; Tim D Prestidge; Mohamed Radhi; Ami J Shah; Kirk R Schultz; Baldeep Wirk; John E Wagner; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-23       Impact factor: 5.742

5.  In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation.

Authors:  Miharu Yabe; Hiromasa Yabe; Satoshi Hamanoue; Hiroyasu Inoue; Masae Matsumoto; Takashi Koike; Hiroyuki Ishiguro; Tsuyoshi Morimoto; Satoshi Arakawa; Toshio Ohshima; Atsuko Masukawa; Hayato Miyachi; Takayuki Yamashita; Shunichi Katob
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

Review 6.  Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.

Authors:  Suneet Agarwal
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

Review 7.  Aplastic anemia in adolescents and young adults.

Authors:  Amy E DeZern; Eva C Guinan
Journal:  Acta Haematol       Date:  2014-09-10       Impact factor: 2.195

8.  Successful bone marrow transplantation in a patient with DNA ligase IV deficiency and bone marrow failure.

Authors:  Bernd Gruhn; Joerg Seidel; Felix Zintl; Raymonda Varon; Holger Tönnies; Heidemarie Neitzel; Astrid Bechtold; Holger Hoehn; Detlev Schindler
Journal:  Orphanet J Rare Dis       Date:  2007-01-15       Impact factor: 4.123

Review 9.  Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in Childhood.

Authors:  Simon Bomken; Roderick Skinner
Journal:  Children (Basel)       Date:  2015-04-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.